Latest market price
153.61
+3.93+2.63%
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 28.71 | EPS (ttm) | 5.35 | Insider Own | 0.87% | Shs Outstand | 69.35M | Perf Week | 2.91% |
| Market Cap | 10.65B | Forward P/E | 19.89 | EPS next Y | 7.72 | Insider Trans | 0.57% | Shs Float | 69.05M | Perf Month | 16.65% |
| Enterprise Value | 11.07B | PEG | 1.66 | EPS next Q | 1.59 | Short Float | 8.15% | Perf Quarter | -7.92% | ||
| Income | 376.00M | P/S | 3.49 | EPS this Y | 33.26% | Short Ratio | 3.32 | Perf Half Y | -10.37% | ||
| Sales | 3.05B | P/B | 7.49 | EPS next Y | 18.68% | ROA | 11.86% | Short Interest | 5.63M | Perf YTD | -45.96% |
| Book/sh | 20.50 | P/C | 19.91 | EPS next 5Y | 17.25% | ROE | 26.69% | 52W High | 354.88 -56.71% | Perf Year | -50.76% |
| Cash/sh | 7.71 | P/FCF | 35.75 | EPS past 3/5Y | 275.36% 103.38% | ROIC | 16.04% | 52W Low | 126.40 21.53% | Perf 3Y | 13.67% |
| Dividend Est. | — | EV/EBITDA | 16.85 | Sales past 3/5Y | 27.55% 24.54% | Gross Margin | 71.08% | Volatility | 2.71% 2.89% | Perf 5Y | -49.17% |
| Dividend TTM | — | EV/Sales | 3.62 | EPS Y/Y TTM | 62.61% | Oper. Margin | 16.89% | ATR (14) | 4.51 | Perf 10Y | 283.26% |
| Dividend Ex-Date | — | Quick Ratio | 1.83 | Sales Y/Y TTM | 29.41% | Profit Margin | 12.29% | RSI (14) | 67.23 | Recom | 2.50 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.48 | EPS Q/Q | 41.88% | SMA20 | 7.49% | Beta | 1.03 | Target Price | 180.59 |
| Payout | 0.00% | Debt/Eq | 0.67 | Sales Q/Q | 23.57% | SMA50 | 8.93% | Rel Volume | 1.04 | Prev Close | 149.68 |
| Employees | 5,400 | LT Debt/Eq | 0.65 | Earnings | Nov 04 | SMA200 | -13.77% | Avg Volume | 1.70M | Price | 153.61 |
| IPO Date | May 15, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 13.11% 1.82% | Net Debt/EBITDA | 0.63 | Volume | 1,772,481 | Change | 2.63% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | Jefferies | Buy | $400 → $190 |
| Oct-06-26 | Initiated | Barclays | Equal Weight | $198 → $150 |
| Aug-06-26 | Reiterated | Robert W. Baird | $248 → $175 | |
| Aug-06-26 | Reiterated | Raymond James | Outperform | $216 → $180 |
| Aug-06-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | $144 |
| Aug-06-26 | Downgrade | Truist Securities | Buy → Hold | $153 |
| Aug-06-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Aug-06-26 | Downgrade | BTIG | Buy → Neutral | |
| Aug-06-26 | Reiterated | Canaccord Genuity | Buy | $249 → $179 |
| Aug-06-26 | Downgrade | Leerink Partners | Outperform → Market Perform | $145 |
Latest News· Times ET
Nov-02-26
Nov-02-2606:05AM
Oct-28-26
Oct-27-26
Oct-26-26
Oct-26-2608:32AM
Oct-20-26
Oct-18-26
Oct-18-2604:41AM
Oct-16-26
Oct-12-26
07:00AM
Insulet Announces Omnipod Discover Now Available in U.S.businesswire.com
Oct-08-26
Oct-01-26
07:00AM
Sep-25-26
10:45AM
04:02AM
Company
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,054 | 2,708 | 2,072 | 1,697 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 883 | 768 | 626 | 537 | — | — | — | — | — | |
| Gross Profit | 2,171 | 1,940 | 1,446 | 1,160 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,308 | 1,165 | 917 | 735 | — | — | — | — | — | |
| Research and Development | 346 | 301 | 220 | 205 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 516 | 474 | 309 | 220 | — | — | — | — | — | |
| Interest Expense | 65 | 80 | 43 | 36 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 44 | -55 | 34 | 31 | — | — | — | — | — | |
| Net Income Before Taxes | 495 | 340 | 300 | 215 | — | — | — | — | — | |
| Income Taxes | 120 | 92 | -118 | 8 | — | — | — | — | — | |
| Consolidated Net Income | 376 | 247 | 418 | 206 | — | — | — | — | — | |
| Net Income From Continuing Operations | 376 | 247 | 418 | 206 | — | — | — | — | — | |
| Net Income | 376 | 247 | 418 | 206 | — | — | — | — | — | |
| EPS (Recurring) | 5.36 | 3.51 | 5.97 | 2.96 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 5.36 | 3.51 | 5.97 | 2.96 | — | — | — | — | — | |
| EPS (Diluted) | 5.35 | 3.48 | 5.78 | 2.94 | — | — | — | — | — | |
| EBITDA | 657 | 510 | 424 | 324 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 28.71 | 81.68 | 45.17 | 73.80 | — | — | — | — | — | |
| Price To Sales Ratio | 3.47 | 7.35 | 8.82 | 8.95 | — | — | — | — | — | |
| Gross Margin | 71.09 | 71.64 | 69.79 | 68.36 | — | — | — | — | — | |
| Operating Margin | 16.90 | 17.50 | 14.91 | 12.96 | — | — | — | — | — | |
| Net Margin | 12.31 | 9.12 | 20.17 | 12.14 | — | — | — | — | — | |
| Shares Outstanding | 69 | 70 | 70 | 70 | — | — | — | — | — | |
| Market Capitalization | 10,599 | 19,897 | 18,275 | 15,189 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McEvoy Ashley | President and CEO | Aug 21 '26 | Buy | 147.47 | 1,100 | 162,217 | 23,731 | Aug 24 |
| BORIO LUCIANA | Director | Jun 03 '26 | Sale | 143.27 | 418 | 59,887 | 4,329 | Jun 04 |
| STONESIFER TIMOTHY C. | Director | Jun 03 '26 | Buy | 143.51 | 2,790 | 400,393 | 9,041 | Jun 04 |
| MINOGUE MICHAEL R | Director | Feb 25 '26 | Buy | 246.23 | 2,030 | 499,847 | 17,483 | Feb 26 |
| McEvoy Ashley | President and CEO | Feb 20 '26 | Buy | 239.35 | 4,300 | 1,029,205 | 13,916 | Feb 23 |
| Frederick Wayne A.I. | Director | Dec 15 '25 | Sale | 293.09 | 1,851 | 542,510 | 2,158 | Dec 16 |
| STONESIFER TIMOTHY C. | Director | Dec 05 '25 | Buy | 311.73 | 962 | 299,884 | 4,591 | Dec 08 |
| Singh Prem | SVP, Global Operations | Sep 08 '25 | Sale | 347.49 | 687 | 238,726 | 3,456 | Sep 09 |
| Cousin Laetitia | SVP, Reg, Quality & Compliance | Sep 08 '25 | Option Exercise | 241.10 | 797 | 192,161 | 4,687 | Sep 09 |
| Cousin Laetitia | SVP, Reg, Quality & Compliance | Sep 08 '25 | Sale | 348.81 | 797 | 278,002 | 3,890 | Sep 09 |
| Benjamin Eric | EVP, CPXO | Aug 21 '25 | Sale | 332.23 | 4,263 | 1,416,296 | 16,736 | Aug 22 |
| Singh Prem | SVP, Global Operations | Aug 07 '25 | Option Exercise | 271.28 | 1,343 | 364,325 | 5,486 | Aug 08 |
| Singh Prem | SVP, Global Operations | Aug 07 '25 | Sale | 320.00 | 1,343 | 429,760 | 4,143 | Aug 08 |
| Singh Prem | SVP, Global Operations | Jun 13 '25 | Option Exercise | 166.62 | 1,257 | 209,441 | 6,470 | Jun 16 |
| Singh Prem | SVP, Global Operations | Jun 13 '25 | Sale | 300.05 | 2,327 | 698,216 | 4,143 | Jun 16 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.